UK Markets open in 1 hr 39 mins

Genfit SA (GNFT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.0800-0.3700 (-8.31%)
At close: 04:00PM EST
4.0000 -0.08 (-1.96%)
After hours: 04:49PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.4500
Open4.1500
Bid0.0000 x 2200
Ask0.0000 x 1000
Day's range4.0000 - 4.2100
52-week range3.0100 - 7.1900
Volume37,740
Avg. volume745,660
Market cap202.885M
Beta (5Y monthly)1.26
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    GENFIT: 2022 Financial Calendar

    Lille, France; Cambridge, MA; January 24, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its provisional financial calendar for 2022. February 28, 2022: Publication of revenue and cash position at December 31, 2021 April 07, 2022: Publication of Full Year 2021 financial statements The 2020 Universal Registration Document and Annual Financial Report (included in the

  • Globe Newswire

    GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

    Lille, France; Cambridge, MA; January 21, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2021: 137,012 shares€512 873.86

  • Globe Newswire

    On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset

    Exclusive rights for a novel early-stage asset acquired from Genoscience Pharma in cholangiocarcinoma in the United States, Canada and EuropePhase 2 clinical program expected to start in 1H 2022Agreement comes on the heels of today’s other announcement of a long-term global strategic partnership with Ipsen including an exclusive licensing agreement for elafibranor, a Phase 3 asset currently evaluated in Primary Biliary Cholangitis Lille, France; Cambridge, MA; December 17, 2021 - GENFIT (Nasdaq